Does the media favor LMAT or MDXG?

In the previous week, MiMedx Group had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for MiMedx Group and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.26 beat MiMedx Group's score of 0.94 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, AXGN or MDXG?

MiMedx Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 9.72 -$15.70M -$0.64 N/A MiMedx Group $418.63M 1.55 $48.58M $0.20 21.80

Is AXGN or MDXG more profitable?

MiMedx Group has a net margin of 7.88% compared to AxoGen's net margin of -13.21%. MiMedx Group's return on equity of 21.03% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% MiMedx Group 7.88% 21.03% 15.92%

Does the media favor AXGN or MDXG?

In the previous week, AxoGen had 1 more articles in the media than MiMedx Group. MarketBeat recorded 7 mentions for AxoGen and 6 mentions for MiMedx Group. AxoGen's average media sentiment score of 1.08 beat MiMedx Group's score of 0.94 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PLSE or MDXG?

In the previous week, MiMedx Group had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 6 mentions for MiMedx Group and 5 mentions for Pulse Biosciences. MiMedx Group's average media sentiment score of 0.94 beat Pulse Biosciences' score of 0.44 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, MDXG or NVCR?

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.55 $48.58M $0.20 21.80 NovoCure $655.35M 2.90 -$136.23M -$1.30 N/A

Is MDXG or NVCR more profitable?

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -21.25%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 7.88% 21.03% 15.92% NovoCure -21.25% -44.00% -15.85%

Does the media refer more to MDXG or NVCR?

In the previous week, NovoCure had 32 more articles in the media than MiMedx Group. MarketBeat recorded 38 mentions for NovoCure and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.94 beat NovoCure's score of 0.73 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 11 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BFLY or MDXG?

In the previous week, Butterfly Network had 14 more articles in the media than MiMedx Group. MarketBeat recorded 20 mentions for Butterfly Network and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.94 beat Butterfly Network's score of 0.09 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MiMedx Group (MDXG) Competitors

$4.36 +0.10 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$4.36 +0.00 (+0.11%)

As of 04:10 PM Eastern

Compare

MDXG vs. LMAT, AXGN, PLSE, NVCR, and BFLY

Should you buy MiMedx Group stock or one of its competitors? MarketBeat compares MiMedx Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiMedx Group include LeMaitre Vascular (LMAT), AxoGen (AXGN), Pulse Biosciences (PLSE), NovoCure (NVCR), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.

How does MiMedx Group compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

LeMaitre Vascular has a net margin of 24.35% compared to MiMedx Group's net margin of 7.88%. MiMedx Group's return on equity of 21.03% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
MiMedx Group	7.88%	21.03%	15.92%

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Comparatively, 2.5% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MiMedx Group had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for MiMedx Group and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.26 beat MiMedx Group's score of 0.94 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has higher earnings, but lower revenue than MiMedx Group. MiMedx Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$256.28M	9.12	$57.73M	$2.71	37.75
MiMedx Group	$418.63M	1.55	$48.58M	$0.20	21.80

LeMaitre Vascular currently has a consensus price target of $112.60, indicating a potential upside of 10.07%. MiMedx Group has a consensus price target of $8.50, indicating a potential upside of 94.95%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

LeMaitre Vascular has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Summary

LeMaitre Vascular and MiMedx Group tied by winning 8 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to AxoGen?

AxoGen (NASDAQ:AXGN) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

MiMedx Group has a net margin of 7.88% compared to AxoGen's net margin of -13.21%. MiMedx Group's return on equity of 21.03% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
MiMedx Group	7.88%	21.03%	15.92%

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, AxoGen had 1 more articles in the media than MiMedx Group. MarketBeat recorded 7 mentions for AxoGen and 6 mentions for MiMedx Group. AxoGen's average media sentiment score of 1.08 beat MiMedx Group's score of 0.94 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.72	-$15.70M	-$0.64	N/A
MiMedx Group	$418.63M	1.55	$48.58M	$0.20	21.80

AxoGen presently has a consensus target price of $46.50, indicating a potential upside of 13.00%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 94.95%. Given MiMedx Group's higher probable upside, analysts plainly believe MiMedx Group is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

AxoGen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Summary

MiMedx Group beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

MiMedx Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	7,013.94	-$72.78M	-$1.10	N/A
MiMedx Group	$418.63M	1.55	$48.58M	$0.20	21.80

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 2.5% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to Pulse Biosciences' net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
MiMedx Group	7.88%	21.03%	15.92%

In the previous week, MiMedx Group had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 6 mentions for MiMedx Group and 5 mentions for Pulse Biosciences. MiMedx Group's average media sentiment score of 0.94 beat Pulse Biosciences' score of 0.44 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences presently has a consensus target price of $32.33, indicating a potential downside of 8.84%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 94.95%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Summary

MiMedx Group beats Pulse Biosciences on 13 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to NovoCure?

MiMedx Group (NASDAQ:MDXG) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -21.25%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
NovoCure	-21.25%	-44.00%	-15.85%

In the previous week, NovoCure had 32 more articles in the media than MiMedx Group. MarketBeat recorded 38 mentions for NovoCure and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.94 beat NovoCure's score of 0.73 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	11 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.55	$48.58M	$0.20	21.80
NovoCure	$655.35M	2.90	-$136.23M	-$1.30	N/A

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MiMedx Group presently has a consensus price target of $8.50, suggesting a potential upside of 94.95%. NovoCure has a consensus price target of $21.20, suggesting a potential upside of 29.98%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

MiMedx Group has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Summary

MiMedx Group beats NovoCure on 11 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Butterfly Network presently has a consensus target price of $5.56, indicating a potential downside of 22.78%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 94.95%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	18.79	-$77.06M	-$0.30	N/A
MiMedx Group	$418.63M	1.55	$48.58M	$0.20	21.80

Butterfly Network has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

In the previous week, Butterfly Network had 14 more articles in the media than MiMedx Group. MarketBeat recorded 20 mentions for Butterfly Network and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.94 beat Butterfly Network's score of 0.09 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has a net margin of 7.88% compared to Butterfly Network's net margin of -73.63%. MiMedx Group's return on equity of 21.03% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
MiMedx Group	7.88%	21.03%	15.92%

Summary

MiMedx Group beats Butterfly Network on 12 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$634.51M	$3.68B	$6.95B	$12.20B
Dividend Yield	N/A	2.17%	2.66%	8.55%
P/E Ratio	21.80	21.89	27.27	23.75
Price / Sales	1.55	296.97	520.59	88.40
Price / Cash	7.69	153.52	49.60	59.05
Price / Book	2.52	7.94	10.24	6.06
Net Income	$48.58M	$23.81M	$3.60B	$336.44M
7 Day Performance	0.93%	-3.95%	-1.80%	-2.14%
1 Month Performance	10.94%	-4.65%	-2.67%	-3.32%
1 Year Performance	-35.79%	32.78%	18.21%	13.49%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	3.5106 of 5 stars	$4.36 +2.3%	$8.50 +95.0%	-37.1%	$634.51M	$418.63M	21.80	870	News Coverage Upcoming Earnings
LMAT LeMaitre Vascular	3.9404 of 5 stars	$101.32 -0.4%	$112.60 +11.1%	+20.0%	$2.32B	$249.60M	37.39	490	Positive News Upcoming Earnings
AXGN AxoGen	2.7945 of 5 stars	$39.86 +0.9%	$46.50 +16.7%	+207.7%	$2.12B	$238.11M	N/A	450	News Coverage Upcoming Earnings Analyst Upgrade
PLSE Pulse Biosciences	1.4126 of 5 stars	$30.58 +5.6%	$30.67 +0.3%	+119.6%	$2.11B	$751K	N/A	140	News Coverage Analyst Forecast
NVCR NovoCure	3.4244 of 5 stars	$16.33 +2.4%	$23.60 +44.5%	+41.4%	$1.89B	$655.35M	N/A	1,605	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. LMAT, AXGN, PLSE, NVCR, and BFLY

How does MiMedx Group compare to LeMaitre Vascular?

Summary

How does MiMedx Group compare to AxoGen?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Summary

How does MiMedx Group compare to NovoCure?

Summary

How does MiMedx Group compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. LMAT, AXGN, PLSE, NVCR, and BFLY

How does MiMedx Group compare to LeMaitre Vascular?

Is LMAT or MDXG more profitable?

Do institutionals & insiders hold more shares of LMAT or MDXG?

Does the media favor LMAT or MDXG?

Which has higher earnings and valuation, LMAT or MDXG?

Do analysts rate LMAT or MDXG?

Which has more risk & volatility, LMAT or MDXG?

Summary

How does MiMedx Group compare to AxoGen?

Is AXGN or MDXG more profitable?

Do institutionals and insiders believe in AXGN or MDXG?

Does the media favor AXGN or MDXG?

Which has preferable valuation and earnings, AXGN or MDXG?

Do analysts rate AXGN or MDXG?

Which has more volatility & risk, AXGN or MDXG?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Which has preferable earnings and valuation, PLSE or MDXG?

Do institutionals & insiders believe in PLSE or MDXG?

Is PLSE or MDXG more profitable?

Does the media prefer PLSE or MDXG?

Do analysts recommend PLSE or MDXG?

Which has more volatility and risk, PLSE or MDXG?

Summary

How does MiMedx Group compare to NovoCure?

Is MDXG or NVCR more profitable?

Does the media refer more to MDXG or NVCR?

Which has higher earnings & valuation, MDXG or NVCR?

Do insiders & institutionals have more ownership in MDXG or NVCR?

Do analysts recommend MDXG or NVCR?

Which has more risk & volatility, MDXG or NVCR?

Summary

How does MiMedx Group compare to Butterfly Network?

Do insiders and institutionals believe in BFLY or MDXG?

Do analysts recommend BFLY or MDXG?

Which has better earnings & valuation, BFLY or MDXG?

Which has more risk and volatility, BFLY or MDXG?

Does the media prefer BFLY or MDXG?

Is BFLY or MDXG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools